Oncology and Radiotherapy ©
Vol.17 Iss.12: 836-843 • REVIEW ARTICLE

A breakthrough in the area of Cardio-Oncology using an Artificial Neural Network

Ji Jie, Liew Kai Bin, Wan Rosalina Wan Rosli

Student, Center for Research & Graduate Studies, University of Cyberjaya, Malaysia

Associate Professor, Faculty of Pharmacy, University of Cyberjaya, Malaysia

Faculty of Pharmacy, Management and Science University, Malaysia

Abstract

Cardio-Oncology (CO) focuses on detecting, monitoring, and treating heart disease brought on by cancer treatments. The realistic is to decrease cancer therapy's harmful effect on the heart and blood vessels. CO help ensure you get the best effective cancer treatment possible with the lowest duration of heart damage. A potential breakthrough oral cancer therapy that selectively destroys cancer cells and leaves healthy tissues unharmed can be provided. Cardiovascular problems associated with cancer treatment include cardiac insufficiency, premature coronary artery disease, valve disease, pericardial damage, and arrhythmias. Artificial Neural Network (ANN) and precision medicine are effective methods for detecting and monitoring cardio-oncology patients that can help promptly detect cancer therapy-related heart damage. Hence, CO-ANN has been changing cancer detection and diagnosis, with enormous promise for improving patient outcomes. Various imaginative solutions continue to approach the sector through skin scans and stomach scans. CO is a cutting-edge interdisciplinary profession that reduces the morbidity and mortality of cancer patients by avoiding and managing cardiovascular toxicities associated with cancer treatments. CO inequalities are variations in the distribution of cardio protective medications, surveillance, and the emergence of unfavorable outcomes linked to cardiac disease brought on by cancer therapy across a range of racial, ethnic, socioeconomic, physical orientation, and demographic categories. Effective treatment for patients with CO utilizes a comprehensive appreciation of the heart disease subspecialties and strong cooperation with specialists in each subspecialty. A multidisciplinary performance with complex patients is likely to yield positive results.

Key Words: Artificial Neural Network, Cardio-Oncology, Patient, Cardiovascular.

Address for correspondence
Ji Jie, Student, Center for Research & Graduate Studies, University of Cyberjaya, Malaysia, Email: 2112-4733@st.cyberjaya.edu.my

Word count: 3823 **Tables:** 00 **Figures:** 07 **References:** 16

Received:-28 October, 2023, Manuscript No. OAR-23- 123002

Editor assigned:- 01 November, 2023, Pre-QC No. OAR-23-123002 (PQ)

Reviewed:- 08 November, 2023, QC No. OAR-23-123002 (Q)

Revised:- 21 November, 2023, Manuscript No. OAR-23-123002 (R)

Published:- 29 November, 2023, Invoice No. J-123002

Overview of a breakthrough in the area of Cardio-Oncology using an artificial neural network

CO is the interface that is an emerging cardiovascular medicine clinical field for a variety of reasons. Cancer treatments that are traditional, targeted, and immune-based therapy has revolutionized oncology by converting killer cancers into chronic illnesses [1]. CO, a field investigating the interaction of cardiovascular illnesses and cancer, has grown in importance since cancer therapy improves survival rates and potentially causes heart disease [2]. A potential new therapy for oral cancer has been demonstrated to selectively kill cancer cells without harming health. However, animal and laboratory tests indicate that the medication has minimal harmful effects [3]. To promote successful cancer therapy while reducing cardiovascular sequelae is the cardio-oncologist's overriding focus; to accomplish that, the risks and gains of the various treatment options must be carefully evaluated [4]. The ANN to interpret Electrocardiograms, echocardiograms, the cerebral cortex scans, and cardiac magnetic resonance imaging has been contributed much to the knowledge of the cardiovascular system [5]. ANN is used to evaluate electrocardiograms, tests scans, and magnetic resonance imaging images of the heart to detect early warning signs and preventable risk factors for cardiovascular illness [6]. CO focuses on locating, tracking, and treating circulatory conditions brought due to cancer treatments. Reduced cardiovascular system adverse effects from cancer therapy are a primary target. CO assists with receiving the best cancer therapy with minimal heart damage [7]. CO inequalities can be characterized as variations in increasing to allocate of

cardioprotective drugs, in monitoring for the emergence of cardiac illness as the consequence of cancer treatment, and in the risk of unfavorable outcomes [8]. High blood pressure, high LDL cholesterol, diabetes, obesity, smoking, poor diet, and inactivity are all potentially significant risk factors for heart disease and stroke.[9]. In treating cancer patients as clinical oncologists, the ultimate target is being able to cure their illness using various therapy modalities targeting the essential tumor and any possible metastases [10]. The cardiotoxicity of anti-tumor treatment has traditionally been the focus of cardio-oncology. A combination of cardiovascular disease with cancer is becoming increasingly common the human life expectancy rises, adding to the complexity of treating multiple conditions [11].

The main contribution of the paper

•CO focuses on controlling cardiovascular disease to ensure patients receive the most effective cancer therapy with fewer difficulties.

•Cancer detection is merely the area CO-ANN is doctors develop resources for cancer detection and diagnosis, with the hope that the technologies can help clinicians spot tumors and abnormalities that can remain undetected.

•With clinical oncologists, the ultimate objective in treating cancer patients is to be able to cure their illness using a variety of therapy modalities focused on the main tumor and potential metastases.

The remainder of the paper, section 2, is related to the work of the existing method; section 3 proposes the technique of CO-ANN to be discussed; the results of the experiments are discussed in section 4, and the study comes to a close in section 5.

Literature survey

Jessica Shank Coviello et al. (2018) discussed reducing Cardio Vascular Risk (CVR), preventing cardiotoxicities, and managing side effects are the core goals of cardio-oncology, which develops core and secondary risk measures through monitoring and treatments [12]. CO is a branch of cardiology that focuses on cancer. This review focuses on the relationship between cancer, cancer therapy, and CVR instead of diving into the cardiotoxicities of certain treatments or radiation. Finally, the developers can explore effective prevention and care techniques for reducing cardiotoxicities in patients undergoing chemotherapeutic or radiation treatments.

Juan Lopez-Mattei et al. (2023) detailed that CO is a rapidly emerging medical subspecialty; currently, Cardiac Computed Tomography (CCT) in the treatment of CO patients has limited regulations [13]. This Expert Consensus statement was set down by specialists in cardiology, radiology, cardiovascular multimodality imaging, and CO. It aims to outlines the most recent research on the use of CCT in CO and offers ideas for how doctors should address any gaps in the evidence.

Ishani Dabral et al. (2021) established Decision Trees (DTs) in cancer detection and neural networks as a prominent study topic in medical science, notably in radiology, heart disease, oncology, and urology. [14]. Cancer is a horrible, diverse illness characterized by aberrant cell tissue proliferation. Millions die annually due to missed illness recognition or late discovery. As a result, precisely recognizing the presence of cancer cells becomes critical for individuals afflicted by cancer, and improved detection and treatment methods are required.

Dimitris Mourtzis et al. (2021) detailed the several strategies and technologies for the diagnosis and treatment of such diseases have been presented [15]. However, Augmented Reality (AR) technology developments can help throughout the diagnostic and prediction procedures. Utilizing AR, the dissertation provides an organizational structure for the purpose of displaying magnetic resonance imaging images, gathering patient data, and analyzing information. Future developments are likewise dealt with in light of the implications found, and the model's early development is provided.

A few drawbacks of a breakthrough in difficulties in contemporary society can be solved by using artificial neural networks in the area of cardio-oncology. Variations in the use of cardioprotective medications, the frequency that adverse events occur, and various factors are essential to the definition of CO inequalities associated with cardiac illness and consequences resulting from cancer treatment based on factors like ethnicity, race, socioeconomic position, orientation in life, and gender. [12] can overcome the disadvantage of [13], [14] and

compare with the proposed method CO-ANN.

Proposed method for CO-ANN

To detect risks for improvement, the commonly offered cardiovascular treatment in cancer patients before the cardio-oncology period needs to be analyzed. Various unanswered concerns and obstacles in cardio-oncology exist, including the underlying pathophysiological processes, enhancing diagnostic accuracy, and implementing particular treatment strategies. Developing sophisticated algorithms that can be utilized in the clinical area might be an essential focus of future trials and registries to maximize resources and create a cost-effective healthcare system. Risk stratification algorithms need future validation and further enhancement by discovering new risk variables. Further, with their growing complexity, unique therapy regimens proceed in tandem with the need to prove interactions among drugs and the combined impact on the circulatory system. The establishment of specialist cardio-oncology units throughout the growth of the control maximizes the cost-benefit ratio of chemotherapeutic therapy with the potential to enhance oncological and cardiac outcomes.



Fig.1. Architecture of Cardio-Oncology.

Figure 1 demonstrates that CO is a relatively young field of clinical medicine that has had rapid expansion in the past ten years. However currently, with new treatments available and a wider range of survivors, the discipline has taken on a new dimension. As patients with metastatic disease approach their final decade of life, clinicians can investigate potential cardiovascular hazards that patients can lack are aware regarding. Collaboration between foundational and translational expertise is necessary to address the many outstanding issues in the area and competent physicians in a cardio-oncology center. That can help develop innovative and safer medication delivery methods free of harmful cardiovascular effects. Cardio-oncology developed over a decade prior, with cardiovascular physicians in several prominent cancer hospitals. To progress in the discipline, a good cardio-oncology program requires the support of a large and diverse cardiovascular division. The crowd hopes that people can appreciate cardio-oncology's unique role in cardiovascular research in reading the compendium that introduces various topic elements. Indeed, the proliferation of reported clinical syndromes and numerous unsolved concerns in the area offer A physician-scientist likely advantage greatly from training in cardio-oncology. The medical professional anticipates that the collection will represent the numerous advancements in clinical, translational, and neutral research in the rapidly growing field of cardiac cancer. For a mechanistic knowledge of cancer and cancer-related toxicity, pre-clinical models are necessary. While delineating some toxicities in rats has been helpful, human models are required. The use of cardiomyocyte-differentiated human induced pluripotent stem cells can extend established models and offer a tailored approach to cardio-oncology.



Fig.2. Advancing the area of cardio-oncology.

Figure 2 shows the growth and extension of cardiac oncology as a specialty in cancer treatment has proceeded at quite an

astonishing rate. CO continues to address a broad range of clinical issues. Fundamental scientific and clinical research concepts identify disease pathways, which in turn underpin cancer therapy effectiveness and give insights into clinically evident cardiovascular damage. An integrated, thorough treatment plan with a diverse team of professionals is obviously necessary to achieve the greatest results. The biennial global cardio-oncology summit brings together researchers, medical professionals, and students from across the world to discuss the most cutting-edge studies and cutting-edge techniques in cardio-oncology. Cancer survivors possess a higher chance of mortality than the general population. A potential risk prediction technique is detecting early heart damage using circulating biomarkers. Initial investigations showed that repeated troponin tests in patients undergoing high-dose anthracycline treatment indicated people with a risk of developing cardiotoxicity and serious cardiovascular events. In individuals with increased troponin, starting angiotensin-converting enzyme inhibitors avoided a deterioration in left ventricular function. Troponin has a significant prospect in detecting myocarditis that results from immune checkpoint inhibitor treatment. The strongest consistent analysis in individuals with suspected myocarditis due to immune checkpoint inhibitors is an elevation in high-sensitivity troponin. Troponin's use as a screening tool appears to be limited in a similar medical environment. Although there has been some exploratory research, there are few detailed guidelines for integrating clinical data, imaging data, and serum biomarkers to risk stratify patients before to and throughout cancer therapy.



Fig.3. Overview of CO-ANN.

Figure 3, A new area of cardiology, as seen in CO, aims to better the detection, diagnosis, and management of cardiovascular problems brought on by various cancer therapies. It is crucial to identify cohorts at risk of developing cardiotoxicity to oncologic treatments and detect cardiotoxicity as soon as is practical in order to enable treatment changes and the implementation of cardioprotective interventions. Cancer therapy issues may endanger both oncology and heart health. Emerging breakthroughs in applying ANN to regularly collected cardiovascular data indicate the capacity of highly complex methods to stratify patients based on tiny pieces of data and significantly enhance the detection of various ailments. These encouraging findings highlight ANN's enticing potential to improve cardio-oncology by facilitating the diagnosis and prevention of undesired cardiotoxicity caused by treatment for cancer. With assessing recent developments in the application of ANN to cardiovascular imaging, people can better monitor, assess, and diagnose the cardiovascular conditions of the cardio-oncology population, reducing cardiovascular toxicity while increasing the efficacy of cancer therapeutics.

$$J_n(k) = \frac{1}{N}[X_n(k)]^2 \quad (1)$$

Where ⟦is J⟧_n (k) the CO prevention, 1/N recognition, and X_n management of cardiovascular consequences of current cancer therapy, X_n (k) including individuals with preexisting cardiovascular illness as well as those who develop it during treatment. Predicting the success or failure of a patient's therapy for heart failure, as well as making a non-invasive diagnostic of coronary artery disease or detecting malignant arrhythmias, are all possible due to ANN.

$$\overline{h(F_n) = \sum_{j=1}^{N} \mu\left(x_{j,\ \hat{x}^{n-1}{}_j}\right) + F_n(yj) + \Delta(F_n)} \quad (2)$$

Where h(F_n) is a cardiovascular treatment are μ(x_(j, ⟦x ^^(n-1)⟧_j)) heart and circulation problems characterized by discomfort, restriction, orF_n (yj) pressure. Discomfort and pain go down the left arm and shoulder, the elbows, the mouth, and Δ(F_n) the feeling breathless and generally struggling for air. Cardiotoxicity is a potential side effect of several cancer

therapy. The heart's ability to pump blood throughout the body may be compromised by CO. Cardiomyopathy is a disorder that affects the heart muscle and makes it work harder to pump blood, and may be the result of and in extreme situations.

$$\dot{x}(m) = y(m) - \partial y(m-1) \quad (3)$$

Where x`(m) a cancer patients, radiotherapy and y(m)can cause severe cardiac damage, even heart failure; radiotherapy-induced ∂y cardiac damage used to be more common, however newer techniques, such as focused beam radiotherapy and (m-1) better shielding, have reduced the incidence of this side effect. Myocardial injury, induced endothelial dysfunction, and altered heart conduction are further side effects of cancer treatment. Therefore, it is crucial for cardiologists in practice to understand the causes, symptoms, and treatment options for cardiovascular problems related to cancer treatment.

RESULT AND DISCUSSION

CO is a relatively new specialty of cardiology that aims to considerably reduce cardiovascular morbidity and death while also enhancing quality of life in cancer survivors. Cancer survival rates have steadily increased, owing mostly to the introduction of new, more effective, and targeted medicines, such as immune checkpoint inhibitors, monoclonal antibodies, therapeutic vaccines, and immune system modulators. Targeted immunotherapies are showing significant promise in the treatment of a variety of malignancies. A potential new oral cancer therapy has been demonstrated to specifically eliminate cancer cells while leaving healthy cells alone. The medicine has only been tested on animals and in labs, but it seems to have no negative effects. A cardio-oncologist is a doctor that helps cancer patients avoid or control heart problems. CO can identify and handle a wide range of cardiac issues brought on by cancer treatment. The term "CO inequities" refers to differences between various racial, ethnic, socioeconomic, sexual, and gender groups in the optimal distribution of cardioprotective drugs, surveillance, and the emergence of negative outcomes associated with cardiac disease caused by cancer treatment.

Dataset discerption: Data on International Cardio-Oncology Society from their 100 patients form 990, provided by Cause IQ, which provides data and tools to help companies develop their nonprofit clients and nonprofits find foundation funding [16].



Fig.4. Evaluation of CO-ANN.

Figure 4 shows that Cardio-oncology is an emerging subspecialty since both cancer and cardiovascular disease are major worldwide killers. As a result of the effects of cancer therapy on the heart, the link between the several diseases was initially recognized. Modern cancer therapies has produced a substantial effect on cancer survival rates. Despite the fact that doctors accomplished great achievements in the treatment of cancer, they now confront fresh challenges. Concerns about cardiac risk and cardiac protection in cancer patients remain in light of the fast emergence of innovative cancer medicines.



Fig.5. Efficiency of CO-ANN.

Figure 5 shows that a cancer patient chemotherapy patient are more likely to get cardiovascular problems. As a result, the availability of potentially life-saving

treatments is restricted, and in certain cases, chemotherapy is outright forbidden. The cardiotoxicity resulting from chemotherapy has been demonstrated to be mitigated through the use of common cardioprotective drugs, according to previous research. However, the therapeutic relevance of these studies has been hampered by small sample numbers and contradictory outcomes. To better determine the medicine and drug class is successful in controlling chemotherapy-induced cardiotoxicity, a comprehensive network meta-analysis utilizing current and high-quality data is preferable.



Fig.6. Testing performed for cardio-oncology.

Figure 6 shows that an electrocardiogram and an echocardiogram aid in the diagnosis of issues affecting the heart's muscle, valves, and rhythm. Certain kinds of chemotherapy and bone stem cell transplants need pre-treatment testing. Despite undergoing cancer therapy, all patients that were exposed to agents and induce cardiotoxicity are required for routine cardiac examinations. Cardio-oncology, a branch of cardiology that has just emerged, focuses on heart issues in cancer patients. Identifying, diagnosing, and treating cardiotoxicity brought on by cancer therapies like chemotherapy and radiation are the main goals of traditional cardio-oncology. Conditions affecting the cardiovascular system are treated using cardiovascular medicine. Chest discomfort, like pain, tightness, or pressure, is a common symptom. Experiencing pain or discomfort that travels down the left side of the body, including the shoulder, elbow, jaw, and back; furthermore, feeling short of breath even while at rest.



Fig.7. Accuracy of CO- ANN.

Figure 7 shows that ANN can utilize the heartbeats' varying lengths for arrhythmia identification with a 98% accuracy rate. Atrial fibrillation and other arrhythmias may be reliably detected using automated ECG interpretation software. In 64% of difficult instances, a generative ANN's differential diagnosis was right, and in 39% of those situations, it was the top diagnosis. ANNs are become an invaluable tool for doctors and scientists as they continue to improve models and approaches for predicting the risk of cardiovascular disease. According to extensive research, using ANN technologies can significantly enhance the ability to predict and diagnose cardiac problems. ANN-guided cardiovascular image analysis, which can precisely, consistently, and inexpensively identify and quantify cardiovascular risk, can improve detection of at-risk or disease features to offer preventative and therapeutic alternatives in cardio-oncology.

Conclusion

COs seek to assess the amount of cardiovascular problems, diagnose heart disease a stage, and provide treatment strategies. The application of ANN in diagnosing patients' population risk for cardiovascular issues owing to cancer therapy is mostly significant and timely in CO, with the potential to dramatically enhance patient care. Medical treatment can be modified for individual patients such that cardioprotective measures are taken early in treatment (resulting in better cardiac and oncologic outcomes. CO-ANN algorithms have the potential to be very useful in echocardiography, with applications ranging from image classification and reconstruction to automated segmentation and

quantification to risk prediction with the inclusion of demographic and medical data. CO focuses on identifying, monitoring, and managing cardiac issues resulting from cancer therapy. The goal is to decrease the impact of cancer therapy on the heart. In order to have the most beneficial cancer therapy with the least amount of cardiac damage, CO is helpful. In effort to reduce patient mortality and enhance their quality of life, that is crucial to implement an effective program to address the issue of cardiotoxicity. Clinics that focus on CO treatment might be useful tools for that target. Rates of cancer therapy throughout follow-up and cumulative CO mortality were tallied as outcomes. The voices classified the cause of mortality as the most probable reason according to patient clinical data, such as the fact that certain patients were predicted to die owing to the development of cancer with post-mortems. As cardio-oncology advances, we may learn more about that generates heart failure and provide customized therapies that are less likely to cause cardiotoxicity.

REFERENCES

1. Moslehi J, Fujiwara K, Guzik T. Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. Cardiovasc Res. 2019;115(5):819-823. Google Scholar | Crossref
2. Dreyfuss AD, Bravo PE, Koumenis C, Ky B. Precision cardio-oncology. J Nucl Med. 2019;60(4):443-450. Google Scholar | Crossref
3. Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40(48):3898-3900. Google Scholar | Crossref
4. Kostakou PM, Kouris NT, Kostopoulos VS, Damaskos DS, Olympios CD. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2019;24:91-100. Google Scholar | Crossref
5. Martinez DSL, Noseworthy PA, Akbilgic O, Herrmann J, Ruddy KJ, Hamid A, et al. Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography. Am Heart J Plus: Cardiol Res Pract. 2022;15:100129. Google Scholar | Crossref
6. Madan N, Lucas J, Akhter N, Collier P, Cheng F, Guha A, et al. Artificial intelligence and imaging: Opportunities in cardio-oncology. Am Heart J Plus: Cardiol Res Pract. 2022;15:100126. Google Scholar | Crossref
7. Sadler D, Arnold A, Herrmann J, Daniele A, Silva CMPC, Ghosh AK, et al. Reaching across the aisle: cardio-oncology advocacy and program building. Curr Oncol Rep. 2021;23:1-13. Google Scholar | Crossref
8. Brown SA, Rhee JW, Guha A, Rao VU. Innovation in precision cardio-oncology during the coronavirus pandemic and into a post-pandemic world. Front Cardiovasc Med. 2020;7:145. Google Scholar | Crossref
9. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80-91. Google Scholar | Crossref
10. Ryan TD, Nagarajan R, Godown J. Pediatric cardio-oncology: development of cancer treatment-related cardiotoxicity and the therapeutic approach to affected patients. Curr Treat Options Oncol. 2019;20:1-16. Google Scholar | Crossref
11. Tocchetti CG, Ameri P, de Boer RA, D'Alessandra Y, Russo M, Sorriento D, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820-1834. Google Scholar | Crossref
12. Coviello JS. Cardiovascular and cancer risk: the role of cardio-oncology. J Adv Pract Oncol. 2018;9(2):160. Google Scholar | Crossref
13. Lopez-Mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, et al. Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Comput Tomogr. 2023;17(1):66-83. Google Scholar | Crossref
14. Dabral I, Singh M, Kumar K. Cancer detection using convolutional neural network. In: Conference Proceedings of ICDLAIR2019. Springer International Publishing; 2021. p. 290-298. Google Scholar | Crossref
15. Mourtzis D, Angelopoulos J, Panopoulos N, Kardamakis D. A smart IoT platform for oncology patient diagnosis based on AI: Towards the human digital twin. Procedia CIRP. 2021;104:1686-1691. Google Scholar | Crossref
16. Kaggle. Heart disease prediction using neural networks. [Internet]. Available from: https://www.kaggle.com/code/bulentsiyah/heart-disease-prediction-using-neural-networks. Google Scholar | Crossref